Residual infectious disease risk in screened blood transfusion from a high-prevalence population: Santa Catarina, Brazil

Transfusion

Volumn 48, Issue 2, 2008, Pages 273-281

  Maresch, Christina ^b   Schluter, Philip J ^a   Wilson, Andrew D ^b   Sleigh, Adrian ^b  

^a AUCKLAND UNIVERSITY OF TECHNOLOGY   (New Zealand)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BLOOD DONOR; BLOOD SAMPLING; BLOOD TRANSFUSION; BRAZIL; CONFIDENCE INTERVAL; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN T CELL LEUKEMIA VIRUS; INCIDENCE; INFECTION; INFECTION RISK; PREVALENCE; VASCULARIZATION; VIRUS TRANSMISSION;

BIOLOGICAL MARKERS; BLOOD DONORS; BLOOD TRANSFUSION; BRAZIL; DISEASE TRANSMISSION; HUMANS; MASS SCREENING; PREVALENCE; RISK FACTORS;

EID: 38349132710     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01521.x     Document Type: Article

References (38)

1. Cruz JR, Perez-Rosales MD. Availability, safety, and quality of blood for transfusion in the Americas. World Hosp Health Serv 2005 41 : 27 31.
2. Schmunis GA, Cruz JR. Safety of the blood supply in Latin America. Clin Microbiol Rev 2005 18 : 12 29.
3. Council of Europe. Guide to the preparation, use and quality assurance of blood components. 7th ed. Strasbourg : Council of Europe Publishing 2001.
4. Seed CR, Kiely P, Keller AJ. Residual risk of transfusion transmitted human immunodeficiency virus, hepatitis B virus, hepatitis C virus and human T lymphotrophic virus. Intern Med J 2005 35 : 592 8.
5. Jackson BR, Busch MP, Stramer SL, AuBuchon JP. The cost-effectiveness of NAT for HIV, HCV, and HBV in whole-blood donations. Transfusion 2003 43 : 721 9.
6. Sloand EM, Pitt E, Klein HG. Safety of the blood supply. JAMA 1995 274 : 1368 73.
7. Zou S, Notari EP, Musavi F, Dodd RY ARCNET Study Group. Current impact of the confidential unit exclusion option. Transfusion 2004 44 : 651 7.
8. Chiavetta JA, Escobar M, Newman A, He YH, Driezen P, Deeks S, Hone D. Incidence and estimated rates of residual risk for HIV, hepatitis C, hepatitis B and human T-cell lymphotropic viruses in blood donors in Canada, 1990-2000. CMAJ 2003 169 : 767 73.
9. Orton SL, Virvos VJ, Williams AE. Validation of selected donor-screening questions: structure, content, and comprehension. Transfusion 2000 40 : 1407 13.
10. Kleinman SH, Busch MP, Korelitz JJ, Schreiber GB. The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infection. Transfus Med Rev 1997 11 : 155 72.
11. Velati C, Romano L, Baruffi L, Pappalettera M, Carreri V, Zanetti AR. Residual risk of transfusion-transmitted HCV and HIV infections by antibody-screened blood in Italy. Transfusion 2002 42 : 989 93.
12. Glynn SA, Kleinman SH, Schreiber GB, Zuck T, McCombs S, Bethel J, Garratty G, Williams AE. Motivations to donate blood: demographic comparisons. Transfusion 2002 42 : 216 25.
13. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian approaches to clinical trials and health-care evaluation. Chichester : Wiley 2005.
14. Congdon P. Bayesian statistical modelling. Chichester : Wiley 2002.
15. Berger JO. Statistical decision theory and Bayesian analysis. 2nd ed. New York : Springer-Verlag 1985.
16. Messias E. Income inequality, illiteracy rate, and life expectancy in Brazil. Am J Public Health 2003 93 : 1294 6.
17. Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS. Version 1.4.1. Cambridge, MRC Biostatistics Unit London : Department of Epidemiology and Public Health, Imperial College School of Medicine 2004. [cited 2004 September 13]. Available from: http://www.mrc-bsu.cam.ac.uk/bugs
18. Brooks SP, Gelman A. Alternative methods for monitoring convergence of iterative simulations. J Comput Graph Stat 1998 7 : 434 55.
19. Kupek EJ. Residual transfusion risk for hepatitis B and C in southern Brazil, 1991-1999. J Viral Hepat 2001 8 : 78 82.
20. Marshall DA, Kleinman SH, Wong JB, AuBuchon JP, Grima DT, Kulin NA, Weinstein MC. Cost-effectiveness of nucleic acid test screening of volunteer blood donations for hepatitis B, hepatitis C and human immunodeficiency virus in the United States. Vox Sang 2004 86 : 28 40.
21. Salles NA, Sabino EC, Barreto CC, Barreto AM, Otani MM, Chamone DF. The discarding of blood units and the prevalence of infectious diseases in donors at the Pro-Blood Foundation/Blood Center of Sao Paulo, Sao Paulo, Brazil [article in Portuguese]. Rev Panam Salud Publica 2003 13 : 111 6.
22. Kupek EJ. The reduction of HIV transfusion risk in southern Brazil in the 1990s. Transfus Med 2001 11 : 75 8.
23. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 : 975 9.
24. Soldan K, Davison K, Dow B. Estimates of the frequency of HBV, HCV, and HIV infectious donations entering the blood supply in the United Kingdom, 1996-2003. Euro Surveill 2005 10 : 17 9.
25. Pillonel J, Laperche S Groupe "Agents Transmissibles par Transfusion" de la Société française de transfusion sanguine; Etablissement français du sang; Centre de transfusion sanguine des armées. Trends in residual risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2002 and impact of viral genome screening (nucleic acid testing) [article in French]. Transfus Clin Biol 2004 11 : 81 6.
26. Gonzalez M, Regine V, Piccinini V, Vulcano F, Giampaolo A, Hassan HJ. Residual risk of transfusion-transmitted human immunodeficiency virus, hepatitis C virus, and hepatitis B virus infections in Italy. Transfusion 2005 45 : 1670 5.
27. Alvarez M, Gonzalez R, Hernández JM, Oyonarte S. Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill 2005 10 : 20 2.
28. Donegan E, Stuart M, Niland JC, Sacks HS, Azen SP, Dietrich SL. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med 1990 113 : 733 9.
29. Bjoro K, Froland SS, Yun Z, Samdal HH, Haaland T. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994 331 : 1607 11.
30. Kleinman SH, Busch MP. The risks of transfusion-transmitted infection: direct estimation and mathematical modelling. Baillieres Best Pract Res Clin Haematol 2000 13 : 631 49.
31. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989 321 : 1494 500.
32. Clemens SA, da Fonseca JC, Azevedo T, Cavalcanti A, Silveira TR, Castilho MC. Hepatitis A and hepatitis B seroprevalence in 4 centers in Brazil [article in Portuguese]. Rev Soc Bras Med Trop 2000 33 : 1 10.
33. Centers for Disease Control and Prevention and the U.S.P.H.S. Working Group. Guidelines for counseling persons infected with human T-lymphotropic virus type I (HTLV-I) and type II (HTLV-II). Ann Intern Med 1993 118 : 448 54.
34. Mendoza-Sassi R, Beria JU, Barros AJ. Outpatient health service utilization and associated factors: a population-based study. Rev Saude Publica 2003 37 : 372 8.
35. Nantachit N, Robison V, Wongthanee A, Kamtorn N, Suriyanon V, Nelson KE. Temporal trends in the prevalence of HIV and other transfusion-transmissible infections among blood donors in northern Thailand, 1990 through 2001. Transfusion 2003 43 : 730 5.
36. Ramos OR, Pedraza FMH. Problemas actuales en la selección de donantes de sangre [article in Spanish]. Revista Cubana de Medicina General Integral 2000 16 : 156 9.
37. Sandborg E, Thornton M. Donor recruitment. Vox Sang 1994 67 Suppl 5 : 8 13.
38. O'Brien SF, Chiavetta JA, Goldman M, Fan W, Nair RC, Sher GD, Vamvakas EC. Predictive ability of sequential surveys in determining donor loss from increasinglystringent variant Creutzfeldt-Jakob disease deferral policies. Transfusion 2006 46 : 461 8.